RESEARCH DIGEST / SAFETY · IV ≠ ORAL · CLASS I RECALL
NAD+ Side Effects and Safety in the Research Literature
Oral precursors were well tolerated in trials. Injectable NAD+ is a different animal: compounded, unapproved, and the subject of a Class I recall for endotoxin. Here is the honest safety ledger.
The short version
On NAD+ side effects and safety, the literature splits cleanly by route. Swallowed precursors (NMN and NR — building blocks the body turns into NAD+) were well tolerated in the trials that tested them, with adverse-event rates close to placebo [4][9]. The route to worry about is the needle: intravenous and injectable NAD+ is a compounded wellness therapy (mixed by a pharmacy, not made by an FDA-approved manufacturer), it rests on very little controlled evidence, and one compounded product was pulled in a Class I recall — the most serious kind — for bacterial endotoxin contamination [18]. None of this is dosing advice. It is the safety record, kept in plain sight.
Tolerability of oral precursors in the trials
Where oral NMN and NR have been tested in randomized trials, the tolerability record is reassuring — within the bounds of what those trials measured. NR at 100, 300 and 1000 mg/day for 8 weeks in healthy overweight adults showed no significant adverse-event difference from placebo at any dose, no flushing, and no elevation of LDL cholesterol [4]. NMN at 250 mg/day for 12 weeks in healthy subjects produced no observed adverse effects, and blood NAD+ returned to baseline after stopping [9]. Even in patient populations the signal held: NR was safe in congestive-heart-failure patients at 1000 mg twice daily for 21 days [7], and NR has been pushed to 3000 mg/day in a Parkinson's-disease safety study. These are short-to-medium-term trials in selected populations, not open-ended safety guarantees — but they describe a well-tolerated profile for the oral precursors, which is exactly what the controlled human evidence is built on.
Injectable and IV NAD+: An Unapproved Compounded Therapy
Injectable and IV NAD+ is where the safety story changes. An NAD injection delivers NAD+ parenterally — straight into a vein or under the skin — bypassing the absorption problem that makes oral NAD+ ineffective. But this is a compounded wellness therapy: it is not FDA-approved, the controlled evidence behind it is minimal (mostly pilot and retrospective data), and infused NAD+ is rapidly cleared from plasma, with one pilot study finding near-complete plasma removal within roughly the first two hours of infusion [17]. Infusions run too fast can cause chest and abdominal discomfort, flushing and nausea. The hardest fact on this page: the FDA issued a Class I recall — its most serious category, reserved for products that can cause serious harm or death — of a compounded NAD+ injection for elevated bacterial endotoxin [18]. Compounded injectables carry real contamination and purity risk; injectable NAD+ should be understood as an unapproved compounded therapy with documented quality problems, not an approved treatment.
The NMN regulatory dispute: contested, not banned
One precursor sits inside an unresolved regulatory fight. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug, which has created marketplace uncertainty about how NMN can be sold [16]. Read this for what it is: a marketplace dispute over a product's regulatory category, not a finding that NMN is unsafe and not a consumer "ban." NAD+ and its precursors — including NMN — are not prohibited by WADA [19]. The point of flagging it here is due diligence: the status is unsettled, the dispute is ongoing, and anyone reading the literature should know the supplement-versus-drug question for NMN is contested rather than closed.
Other documented concerns
Two further caveats appear in the literature. First, supplement-grade products vary widely in purity and actual content, and third-party testing is not guaranteed [16] — the label and the contents are not always the same thing. Second, a theoretical, context-dependent concern: because NAD+ supports the metabolism of proliferating cells, raising it could in principle fuel existing cancers, and NAD+ has dual, context-dependent roles in oncology, so caution has been advised in cancer populations [16]. These are noted as documented concerns in the research, not as established harms — and as with everything here, the digest gives no dosing or administration instructions.
What is the downside of taking NAD+?
Reviews note that translation to hard clinical outcomes is unproven [15], that IV NAD+ rests on minimal controlled evidence, and that compounded injectables carry contamination risk — the FDA has issued a Class I recall of a compounded NAD+ injection for elevated endotoxin [18]. Oral precursors themselves were well tolerated in trials [4][9].
Is it safe to take NAD daily?
Oral precursors were well tolerated in daily-dosing trials — for example NR at 100–1000 mg/day for 8 weeks with no significant adverse-event difference from placebo [4], and NMN at 250 mg/day for 12 weeks with no safety signals [9]. This describes research findings, not a recommendation, and no dosing guidance is given here.
What is an NAD injection?
An NAD injection delivers NAD+ parenterally, into a vein (IV) or under the skin. Injectable and IV NAD+ is a compounded wellness therapy, not FDA-approved, with limited controlled evidence and documented quality risks — including a Class I recall of a compounded NAD+ injection for elevated endotoxin [18].
When should you inject NAD+?
Studies do not establish injection timing. Reported wellness protocols use multi-hour infusions, but no controlled trial defines an optimal schedule, and infused NAD+ is rapidly cleared from plasma anyway [17]. This digest gives no dosing or administration instructions of any kind.
Is NAD safe?
Oral NMN and NR were well tolerated in trials [4][9] and are not WADA-prohibited [19]. IV and compounded NAD+ carries contamination risk — a Class I endotoxin recall is on the record [18]. This summarizes research, not a safety endorsement, and gives no dosing advice.
How long do NAD side effects last?
Timing is study-specific. In tolerability reports, IV NAD+ infusion-related symptoms — flushing, chest or abdominal discomfort, nausea when run fast — resolved on completing the infusion. Oral-precursor trials reported few adverse events overall [4][9], and with NMN blood NAD+ itself returned to baseline within about 16 weeks of stopping [9].